Physician profile
Ashley D Wise
NPI 1912668799
$8,142.68
in general payments reported to CMS, 2019-2025
27 companies · $3,731 in 2025
The $3,731 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $738 · 2023: $2,123 · 2024: $1,425 · 2025: $3,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,811 · Consulting Fee: $450 · Education: $18.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,810.54 |
| Consulting Fee | $450.00 |
| Education | $18.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,207.33 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,478.29 | 2022-2025 | |
| Janssen Biotech, INC. | $1,090.16 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $479.81 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $404.92 | 2022-2025 | Entyvio |
| Genzyme Corporation | $283.01 | 2022-2025 | |
| Madrigal Pharmaceuticals | $200.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $199.09 | 2023-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $179.30 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $177.19 | 2022-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $161.72 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $161.71 | 2022-2024 | Linzess |
| Daiichi Sankyo INC. | $153.86 | 2022-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $153.46 | 2024-2025 | Voquezna |
| Amgen INC. | $125.00 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.31 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $100.03 | 2022-2025 | Livdelzi |
| Pfizer INC. | $97.71 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $93.51 | 2022-2023 | |
| Celltrion USA INC. | $62.43 | 2024-2025 | Vegzelma, Zymfentra |
| Organon LLC | $58.54 | 2025 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $53.60 | 2023-2025 | Zenpep |
| Redhill Biopharma INC. | $34.68 | 2023 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $20.28 | 2024 | |
| Braintree Laboratories, INC. | $15.73 | 2022 | |
| Celgene Corporation | $15.47 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $12.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.